EDGAR·FLOW

Larimar Therapeutics, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Larimar submitted a rolling Biologics License Application (BLA) to the FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia (FA) in adults and pediatric patients, using skin frataxin (FXN) as a novel surrogate endpoint. The company has $128.7M in cash (runway into late Q2 2027), reported Q3 2026 net loss of $31.1M ($0.29/share), and projects potential U.S. approval in mid-2027 with Q3 2027 launch if approved; Phase 3 FORWARD-FA trial continues enrolling.
Why this rating

Major regulatory milestone (BLA submission) for lead asset in ~$95M company; material funding cushion; multiple near-term catalysts (FDA acceptance, approval, launch) over next 12 months; high execution risk on approval and commercialization.

Tradability signal
NO TRADE

No trade: already up 12.9% on the news and the fade evidence is too weak. Similar past filings (508 in this cell) moved -0.04% in the called direction over 4 hrs; shrunk for sample size that's a -0.04% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.90 ▼ 5.35%
at our read · unknown
$3.06
+10 min · unknown
$3.26 ▲ 6.40%
+30 min · unknown
$3.07 ▲ 0.26%
+1 hr · unknown
$3.10 ▲ 1.01%
+4 hrs · unknown
$2.90 ▼ 5.52%

The stock had already moved +5.66% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ LRMR · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.